Effect of Antihypertensive Agents Over Sleep Apnea

Model scores of the 29,894 trials active now.

Model score 10% for any early termination, 5% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 20% of the time (381 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2016-02-29. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Accepts healthy volunteers: No (raises risk) · Who can join
• Sponsor's past termination rate: 6.1% (lowers risk) · Sponsor's track record
• Minimum age: 40 (lowers risk) · Who can join
• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: hypertensionstrokepressurecontrolleduse of
  Phrases that lowered it: the effectcriteria patientstrialeffect oftreatment
• Phase: 3 (lowers risk) · Design
• Trials the sponsor started in the prior 2 years: 51 (lowers risk) · Sponsor's track record
• Blinding: quadruple (lowers risk) · Design
• Design: parallel (raises risk) · Design
• Disease area, neurology: Yes (raises risk) · Disease area
• Drug's FAERS reports with a death: 10.8% (lowers risk) · Drug's FDA history
• Disease area, cancer: No (lowers risk) · Disease area
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Drug's FAERS reports marked serious: 76.8% (lowers risk) · Drug's FDA history
• Primary purpose: treatment (raises risk) · Design
• Disease area, respiratory: Yes (raises risk) · Disease area
• Keywords listed: 6 (lowers risk) · Design
• Disease area, cardiovascular: Yes (raises risk) · Disease area
• Drugs with FDA adverse-event history: 3 (lowers risk) · Drug's FDA history
• Has a data monitoring committee: No (lowers risk) · Design

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Study of Cardiovascular Disease and Obstructive Sleep Apnea NCT01637623 · started 2012 · scored riskier than 46% of active trials completed
• Acetazolamide for Obstructive Sleep Apnea to Improve Heart Health NCT05616260 · started 2022 · scored riskier than 23% of active trials completed
• Effect of Antihypertensive Agents on Diastolic Function in Patients With Sleep Apnea NCT02896621 · started 2014 · scored riskier than 16% of active trials completed
• A Short Term Open, Randomized Cross-over Trial Exploring the Effect of Carbonic Anhydrase Inhibition by Acetazolamide on Sleep Apnea Associated Hypertension and Vascular Dysfunction NCT02220803 · started 2014 · scored riskier than 12% of active trials completed
• Combination Drug-Therapy for Patients With Untreated Obstructive Sleep Apnea NCT04639193 · started 2020 · scored riskier than 44% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.